
## Immuno-Oncology: the new horizon in lung cancer

Wednesday 26 March 2014 18.30–19.30

PALEXPO Rooms A & B Geneva, Switzerland







## Chair's invitation

## Dear colleagues,

On behalf of Bristol-Myers Squibb, it is my pleasure to invite you to a satellite symposium entitled 'Immuno-Oncology: the new horizon in lung cancer treatment', as part of the 2014 European Lung Cancer Conference in Geneva, Switzerland.

In this symposium, we will discuss the role of the immune system in oncology, highlighting the immunogenic nature of lung cancer and the rationale for the immuno-oncology approach in this setting. The data emerging from the ongoing development of novel agents that modulate immune regulatory checkpoints in patients with lung cancer is very promising. Early clinical data from several exploratory agents suggests the potential for achieving prolonged clinical benefit and provides new hope for these individuals.

Other topics will include efficacy and safety profiles from the latest clinical trial data for immune checkpoint inhibitors in lung cancer when used alone or in combination across a range of treatment settings. Finally, because immuno-oncology agents act via the immune system and are not tumour type specific, we will discuss the potentially broad clinical application of these agents.

We anticipate that the high levels of interaction and analysis provided by the symposium will inform and benefit your clinical practice, and look forward to welcoming you in Geneva.


Martin Rec

Germany

## **Programme**



Martin Reck, Germany



Martin Reck

18.50 Targeting the immune system: clinical experience

Julien Mazieres, France

19.05 Beyond conventional treatment modalities for NSCLC: key considerations for Immuno-Oncology

Luis Paz-Ares, Spain

19.20 Concluding remarks, and questions and answers

Martin Reck

19.30 Close